Journal of Literature Pharmacy Sciences

Anjiyotensin Dönüştürücü Enzim İnhibitörlerinin Alzheimer Hastalığında Kullanım Potansiyeli: Avantaj ve Dezavantajları: Geleneksel Derleme
Treatment Potential of Angiotensin Converting Enzyme Inhibitors in Alzheimer's Disease: Pros and Con: Traditional Review
Cemre BAŞOLa, Zeliha KERRYb, Günay YETİK ANACAKb
aDüzce Üniversitesi Sağlık Bilimleri Enstitüsü, Düzce, Türkiye
bEge Üniversitesi Eczacılık Fakültesi, Farmakoloji ABD, İzmir, Türkiye
J Lit Pharm Sci. 2022;11(2):86-93
doi: 10.5336/pharmsci.2021-87228
Article Language: TR
Full Text
ÖZET
 Alzheimer, bilişsel fonksiyonlarda kayıplara neden olan nörodejeneratif bir hastalıktır. Alzheimer'ın patogenezinde toksik amiloidbeta (Aß) peptid birikimi, tau proteinlerinin hiperfosforilasyonu ve asetilkolin seviyelerindeki azalma yatmaktadır. Bu kapsamda, kolinesteraz inhibitörleri ve N-metil-D-aspartat antagonistleri ileri Alzheimer tedavisinde kullanılmaktadırlar. Ancak yine de ileri veya orta düzeydeki Alzheimer'da daha etkin tedavilerin bulunmasına ihtiyaç vardır. Bu nedenle bilim insanları, Alzheimer'ın patolojisindeki moleküler yolakları ve bu süreçleri etkileyebilecek ilaçları araştırmaktadırlar. Alzheimer'da anjiyotensin dönüştürücü enzim [angiotensin converting enzyme (ACE)] inhibitörlerinin kullanımına yönelik çelişkili çalışmalar mevcuttur. İn vitro çalışmalar, ACE'nin P maddesi seviyesini ve peroksizom proliferatör aktive reseptör-gama aktivitesini azaltarak, Aß yıkımını azaltabileceğini göstermiştir. Ayrıca ACE'nin asetilkolin salınım inhibisyonunu ve Aß birikimini artırdığı kanıtlanmıştır. Bu kapsamda, ACE inhibitörlerinin Alzheimer prognozunu azalttığını gösteren klinik çalışmalar mevcuttur. Bu çalışmaların tersine, ACE inhibitörlerinin Alzheimer'da demans riskini artırdığına yönelik klinik bulgular da vardır. ACE'nin aynı zamanda N terminal bölgesi ile Aß birikimini direkt azalttığının gösterilmiş olması bu paradoksu açıklayabilir. Dolayısıyla ACE inhibitörleri, Alzheimer tedavisinde Aß birikimini direkt artırarak düşman, ancak 'downstream' mekanizmalar üzerinden etki göstererek dost bir yaklaşım ortaya koyabilir. Bütün bu veriler göz önüne alındığında, Alzheimer tedavisi için santral sinir sistemine girebilen ve N terminal bölgesini değil, C terminal bölgesini inhibe eden ACE inhibitörlerinin geliştirilmesi umut verici bir hedef olabilir. Bu derlemede, ACE inhibitörlerinin Alzheimer gelişimindeki olumlu ve olumsuz rolleri, mekanizmaları, santral etkili ve aktif bölge seçici ACE inhibitörlerinin ayrımı incelenmiştir.

Anahtar Kelimeler: Alzheimer hastalığı; anjiyotensin dönüştürücü enzim inhibitörleri; santral sinir sistemi; aktif bölge seçici inhibitörler
ABSTRACT
 Alzheimer's is a neurodegenerative disease that can lead on loss of cognitive functions. Alzheimer's pathology includes toxic amyloid-beta (Aß) peptide accumulation, hyperphosphorylation of tau proteins, and acetylcholine levels reduction. In this context, cholinesterase inhibitors and N-methyl-D-aspartate antagonists are used in the treatment of advanced Alzheimer's. However, there is still a need for more effective treatments for advanced or moderate Alzheimer's. Therefore, scientists are investigating the molecular pathways involved in Alzheimer's pathology and the drugs that may affect these processes. Conflicting studies are available intended for angiotensin converting enzyme (ACE) inhibitors usage in Alzheimer's. In vitro studies have shown that ACE can reduce Aß destruction by reducing substance P levels and peroxisome proliferatör receptor-gamma activity. Also, it has been proven to ACE increases acetylcholine release inhibition and Aß accumulation. In this context, there are clinical studies have shown that ACE inhibitors decrease Alzheimer's prognosis. On the contrary to these studies, there are also clinical findings suggesting that ACE inhibitors increase dementia in Alzheimer's. Recent studies have shown that ACE also reduces Aß accumulation directly by N-terminal may explain this paradox. Therefore, ACE inhibitors can reveal a hostile approach by direct increasing Aß accumulation, or friendly approach by acting through downstream mechanisms. Given these datas, development of ACE inhibitors that can enter the central nervous system and inhibit C-terminal, but not N-terminal, may be promising target for Alzheimer's treatment. In this review, the positive-negative roles and mechanisms of ACE inhibitors in Alzheimer's development, seperation of centrally acting and active site selective ACE inhibitors are examined.

Keywords: Alzheimer's disease; angiotensin converting enzyme inhibitors; central nervous system; active site selective inhibitors
REFERENCES:
  1. Beach TG. The history of Alzheimer's disease: three debates. J Hist Med Allied Sci. 1987;42(3):327-49. [Crossref]  [PubMed] 
  2. Kim KY, Wood BE, Wilson MI. Risk factors for Alzheimer's disease: an overview for clinical practitioners. Consult Pharm. 2005;20(3):224-30. [Crossref]  [PubMed] 
  3. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006;57:513-33. [Crossref]  [PubMed] 
  4. Cankurtaran M, Yavuz BB, Cankurtaran ES, Halil M, Ulger Z, Ariogul S. Risk factors and type of dementia: vascular or Alzheimer? Arch Gerontol Geriatr. 2008;47(1):25-34. [Crossref]  [PubMed] 
  5. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018;14:450-64. [Crossref]  [PubMed]  [PMC] 
  6. Wong CW, Quaranta V, Glenner GG. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A. 1985;82(24):8729-32. [Crossref]  [PubMed]  [PMC] 
  7. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-339. [Crossref]  [PubMed]  [PMC] 
  8. Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22. [Crossref]  [PubMed]  [PMC] 
  9. Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev. 2006;127(2):148-57. [Crossref]  [PubMed] 
  10. Octave JN, Pierrot N. [Alzheimer's disease: cellular and molecular aspects]. Bull Acad Natl Med. 2008;192(2):323-31; discussion 331-2. [Crossref]  [PubMed] 
  11. Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76(1):116-29. [Crossref]  [PubMed]  [PMC] 
  12. Liu Q, Wu J. Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotoxicity. Acta Pharmacol Sin. 2006;27(10):1277-86. [Crossref]  [PubMed] 
  13. Farlow MR. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics. 2004;59(6):22-7. [PubMed] 
  14. Khurana V, Goswami B. Angiotensin converting enzyme (ACE). Clin Chim Acta. 2022;524:113-22. [Crossref]  [PubMed] 
  15. Baudin B, Berard M, Carrier JL, Legrand Y, Drouet L. Vascular origin determines angiotensin I-converting enzyme expression in endothelial cells. Endothelium. 1997;5(1):73-84. [Crossref]  [PubMed] 
  16. Defendini R, Zimmerman EA, Weare JA, Alhenc-Gelas F, Edros EG. Hydrolysis of enkephalins by human converting enzyme and localization of the enzyme in neuronal components of the brain. Adv Biochem Psychopharmacol. 1982;33:271-80. [PubMed] 
  17. Zubenko GS, Volicer L, Direnfeld LK, Freeman M, Langlais PJ, Nixon RA. Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy. Brain Res. 1985;328(2):215-21. [Crossref]  [PubMed] 
  18. Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci. 2020;27(3):905-12. [Crossref]  [PubMed]  [PMC] 
  19. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281(5383):1640-5. [Crossref]  [PubMed] 
  20. Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol. 1991;200(2-3):289-92. [Crossref]  [PubMed] 
  21. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008;34(2):181-93. [Crossref]  [PubMed] 
  22. AbdAlla S, Langer A, Fu X, Quitterer U. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. Int J Mol Sci. 2013;14(8):16917-42. [Crossref]  [PubMed]  [PMC] 
  23. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, et al. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res. 2009;1(2):163-77. [PubMed]  [PMC] 
  24. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001;22(4):541-6. [Crossref]  [PubMed] 
  25. Arregui A, Perry EK, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J Neurochem. 1982;38(5):1490-2. [Crossref]  [PubMed] 
  26. He M, Ohrui T, Maruyama M, Tomita N, Nakayama K, Higuchi M, et al. ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease. Neurology. 2006;67(7):1309-10. [Crossref]  [PubMed] 
  27. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis. 2007;26(1):27-35. [Crossref]  [PubMed] 
  28. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Catto AJ, Hooper NM. Plasma angiotensin-converting enzyme in Alzheimer's disease. J Alzheimers Dis. 2009;16(3):609-18. [Crossref]  [PubMed] 
  29. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686-92. [Crossref]  [PubMed] 
  30. Lebouvier T, Chen Y, Duriez P, Pasquier F, Bordet R. Antihypertensive agents in Alzheimer's disease: beyond vascular protection. Expert Rev Neurother. 2020;20(2):175-187. [Crossref]  [PubMed] 
  31. Takane K, Hasegawa Y, Lin B, Koibuchi N, Cao C, Yokoo T, et al. Detrimental effects of centrally administered angiotensin II are enhanced in a mouse model of Alzheimer disease independently of blood pressure. J Am Heart Assoc. 2017;6(4):e004897. [Crossref]  [PubMed]  [PMC] 
  32. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62(5):810-7. [Crossref]  [PubMed]  [PMC] 
  33. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, et al. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res. 2002;91(11):1038-45. [Crossref]  [PubMed] 
  34. Gebre AK, Altaye BM, Atey TM, Tuem KB, Berhe DF. Targeting renin-angiotensin system against Alzheimer's disease. Front Pharmacol. 2018;9:440. [Crossref]  [PubMed]  [PMC] 
  35. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS One. 2011;6(1):e16037. [Crossref]  [PubMed]  [PMC] 
  36. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421-4. [Crossref]  [PubMed] 
  37. Takai S, Jin D, Kimura M, Kirimura K, Sakonjo H, Tanaka K, et al. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats. Hypertens Res. 2007;30(12):1231-7. [Crossref]  [PubMed] 
  38. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000;20(2):558-67. [Crossref]  [PubMed]  [PMC] 
  39. D'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, Aet al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J. 2005;391(Pt 3):693-8. [Crossref]  [PubMed]  [PMC] 
  40. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 2008;1244:164-72. [Crossref]  [PubMed]  [PMC] 
  41. Kaur B, Singh N, Jaggi AS. Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol. 2009;23(5):557-66. [Crossref]  [PubMed] 
  42. Singh B, Sharma B, Jaggi AS, Singh N. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-γ agonistic property. J Renin Angiotensin Aldosterone Syst. 2013;14(2):124-36. [Crossref]  [PubMed] 
  43. Olajide OJ, Gbadamosi IT, Yawson EO, Arogundade T, Lewu FS, Ogunrinola KY, et al. Hippocampal degeneration and behavioral impairment during Alzheimer-like pathogenesis involves glutamate excitotoxicity. J Mol Neurosci. 2021;71(6):1205-20. [Crossref]  [PubMed] 
  44. Govindpani K, Calvo-Flores Guzmán B, Vinnakota C, Waldvogel HJ, Faull RL, Kwakowsky A. Towards a better understanding of GABAergic remodeling in Alzheimer's disease. Int J Mol Sci. 2017;18(8):1813. [Crossref]  [PubMed]  [PMC] 
  45. Sengul G, Coskun S, Cakir M, Coban MK, Saruhan F, Hacimuftuoglu A. Neuroprotective effect of ACE inhibitors in glutamate-induced neurotoxicity: rat neuron culture study. Turk Neurosurg. 2011;21(3):367-71. [Crossref]  [PubMed] 
  46. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med. 2009;169(13):1195-202. [Crossref]  [PubMed]  [PMC] 
  47. Fazal K, Perera G, Khondoker M, Howard R, Stewart R. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease. BJPsych Open. 2017;3(4):158-64. [Crossref]  [PubMed]  [PMC] 
  48. Gao Y, O'Caoimh R, Healy L, Kerins DM, Eustace J, Guyatt G, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013;3(7):e002881. [Crossref]  [PubMed]  [PMC] 
  49. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63(7):1324-5. [Crossref]  [PubMed] 
  50. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc. 2004;52(4):649-50. [Crossref]  [PubMed] 
  51. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res. 2010;1352:176-86. [Crossref]  [PubMed] 
  52. O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, et al. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J Alzheimers Dis. 2014;40(3):595-603. [Crossref]  [PubMed] 
  53. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 2011;25(9):2911-20. [Crossref]  [PubMed] 
  54. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6(2):143-50. [Crossref]  [PubMed] 
  55. Ashby EL, Kehoe PG. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin Investig Drugs. 2013;22(10):1229-42. [Crossref]  [PubMed] 
  56. Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer's disease: progress toward disease prevention and treatment? J Alzheimers Dis. 2018;62(3):1443-66. [Crossref]  [PubMed]  [PMC] 
  57. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280(45):37644-50. [Crossref]  [PubMed]  [PMC] 
  58. Zou K, Maeda T, Watanabe A, Liu J, Liu S, Oba R, et al. Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem. 2009;284(46):31914-20. [Crossref]  [PubMed]  [PMC] 
  59. Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413-31. [Crossref]  [PubMed] 
  60. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012;30 Suppl 2:S251-68. [Crossref]  [PubMed] 
  61. Larmuth KM, Masuyer G, Douglas RG, Schwager SL, Acharya KR, Sturrock ED. Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme. FEBS J. 2016;283(6):1060-76. [Crossref]  [PubMed]  [PMC] 
  62. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci. 2005;21(3):733-40. [Crossref]  [PubMed] 
  63. Polakovičová M, Jampílek J. Advances in structural biology of ACE and development of domain selective ACE-inhibitors. Med Chem. 2019;15(6):574-87. [Crossref]  [PubMed] 
  64. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31(4):912-7. [Crossref]  [PubMed] 
  65. Redelinghuys P, Nchinda AT, Sturrock ED. Development of domain-selective angiotensin I-converting enzyme inhibitors. Ann N Y Acad Sci. 2005;1056:160-75. [Crossref]  [PubMed] 
  66. Fuchs S, Xiao HD, Hubert C, Michaud A, Campbell DJ, Adams JW, et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension. 2008;51(2):267-74. [Crossref]  [PubMed] 
  67. Costerousse O, Jaspard E, Allegrini J, Wei L, Alhenc-Gelas F. [Angiotensin converting enzyme (kininase II). Molecular and physiological aspects]. C R Seances Soc Biol Fil. 1992;186(6):586-98. [PubMed] 
  68. Perich RB, Jackson B, Johnston CI. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur J Pharmacol. 1994;266(3):201-11. [Crossref]  [PubMed] 
  69. Douglas RG, Sharma RK, Masuyer G, Lubbe L, Zamora I, Acharya KR, et al. Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. Clin Sci (Lond). 2014;126(4):305-13. [Crossref]  [PubMed]  [PMC] 
  70. Watermeyer JM, Kröger WL, O'Neill HG, Sewell BT, Sturrock ED. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J. 2010;428(1):67-74. [Crossref]  [PubMed] 
  71. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992;267(19):13398-405. [Crossref]  [PubMed] 
  72. Burger D, Reudelhuber TL, Mahajan A, Chibale K, Sturrock ED, Touyz RM. Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Clin Sci (Lond). 2014;127(1):57-63. [Crossref]  [PubMed] 
  73. Bevilacqua M, Vago T, Rogolino A, Conci F, Santoli E, Norbiato G. Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J Cardiovasc Pharmacol. 1996;28(4):494-9. [Crossref]  [PubMed] 
  74. Michaud A, Williams TA, Chauvet MT, Corvol P. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol. 1997;51(6):1070-6. [Crossref]  [PubMed] 
  75. Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007;577(1-3):1-6. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com